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Objective: We sought to determine whether methylprednisolone, when
administered to patients undergoing cardiac surgery, is able to ward off the
detrimental hemodynamic and pulmonary alterations associated with car-
diopulmonary bypass.
Methods: After institutional review board approval and informed consent
was obtained, 90 patients scheduled for elective cardiac surgery were ran-
domized to 1 of 3 groups. Group 30MP patients received 30 mg/kg intra-
venous methylprednisolone during sternotomy and 30 mg/kg during initia-
tion of cardiopulmonary bypass, group 15MP patients received 15 mg/kg
methylprednisolone at the same 2 times, and group NS patients received sim-
ilar volumes of isotonic sodium chloride solution at the same 2 times.
Perioperative care was standardized, and all caregivers were blinded to treat-
ment group. Various hemodynamic and pulmonary measurements were
obtained perioperatively, as well as fluid balance, weight, peak postoperative
blood glucose level, and tracheal extubation time.
Results: Demographic and clinical characteristics of patients and intraopera-
tive data were similar among the 3 groups. Patients receiving methylpred-
nisolone (either dose) exhibited significantly increased cardiac index 
(P = .0006), significantly decreased systemic vascular resistance (P = .0005),
and significantly increased shunt flow (P = .0020) during the immediate
postoperative period. All 3 groups exhibited significant increases in alveolar-
arterial oxygen gradient (P < .0001), significant decreases in dynamic lung
compliance (P < .0001), and significant decreases in static lung compliance
(P < .0001) during the immediate postoperative period, with no differences
between groups. Perioperative fluid balance and weights were similar
between groups. A statistically significant difference in peak postoperative
blood glucose level existed (P = .016) among group NS (234 ± 96 mg/dL),
group 15MP (292 ± 93 mg/dL), and group 30MP (311 ± 90 mg/dL). In
patients extubated within 12 hours of intensive care unit arrival, a statistical-
ly significant difference in extubation times existed (P = .025) between
group NS (5.7 ± 2.3 hours), group 15MP (5.9 ± 2.2 hours), and group 30MP
(7.5 ± 2.7 hours).
Conclusions: Methylprednisolone, as used in this investigation, offers no
clinical benefits to patients undergoing elective coronary artery bypass graft-
ing with cardiopulmonary bypass and may in fact be detrimental by initiat-
ing postoperative hyperglycemia and possibly hindering early postoperative
tracheal extubation for undetermined reasons.  (J Thorac Cardiovasc Surg
2001;121:561-9)
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Cardiopulmonary bypass (CPB) exposes blood tolarge areas of synthetic materials that trigger the
production and release of numerous chemotactic and
vasoactive substances.1 This ensuing abnormal whole-
body inflammatory response can complicate the post-
operative period by causing major organ dysfunction.
Traditionally, methylprednisolone has been adminis-
tered to patients undergoing cardiac surgery to ward off
these detrimental physiologic alterations, yet few well-
controlled investigations exist, and use of the drug in
this setting remains controversial. Our group was the
first to rigorously examine use of methylprednisolone
in patients undergoing coronary artery bypass grafting
(CABG) and early extubation.2,3 Somewhat surprising-
ly, we found that methylprednisolone (30 mg/kg during
sternotomy and 30 mg/kg during initiation of CPB)
caused larger increases in postoperative alveolar-arteri-
al (A-a) oxygen gradient and shunt flow, was unable to
prevent postoperative decreases in lung compliance,
was associated with a higher likelihood of requiring
postoperative hemodynamic support, and prolonged
tracheal extubation times when compared with placebo
controls.2,3 These results indicate that use of the drug in
this setting may hinder early tracheal extubation.2,3
This study was undertaken to determine whether these
unexpected results could be duplicated and possibly
ascertain why methylprednisolone was detrimental in
this setting. Because larger doses of methylpred-
nisolone may induce sodium and water retention,
which may initiate pulmonary edema in susceptible
patients,4 this investigation assessed perioperative fluid
balance and weights in study patients along with stan-
dard pulmonary and hemodynamic parameters.
Furthermore, 2 different doses of methylprednisolone
(30 mg/kg twice and 15 mg/kg twice) are compared
with placebo controls.
Methods
After institutional review board approval and informed
consent were obtained, 90 patients scheduled for elective
CABG and early extubation were studied. At our institution,
we view all patients scheduled for elective CABG as candi-
dates for early extubation, including those undergoing reop-
erations and those with decreased left ventricular function
(ejection fraction < 40%). Patients receiving preoperative
steroids or who had undergone previous lung surgery were
excluded from participation. Patients requiring preoperative
intravenous inotropic or vasoactive drugs, intra-aortic balloon
support, supplemental oxygen, or mechanical ventilation
were excluded.
Each patient was randomized to 1 of 3 groups. Two groups
received intravenous methylprednisolone sodium succinate
(A-Methapred; Abbott Laboratories, North Chicago, Ill), and
1 group received intravenous isotonic sodium chloride solu-
tion. Group 30MP patients received 30 mg/kg intravenous
methylprednisolone during sternotomy and 30 mg/kg during
initiation of CPB, group 15MP patients received 15 mg/kg of
intravenous methylprednisolone at the same 2 times, and
group NS patients received similar volumes of intravenous
isotonic sodium chloride solution at the same 2 times. An
anesthesia research nurse performed the randomization and
prepared the 2 syringes of blinded solution that were admin-
istered by the anesthesiologist managing the case. All physi-
cians and nursing staff caring for the patients perioperatively
were unaware of treatment group.
The intraoperative anesthetic technique was standardized and
consisted of intravenous fentanyl (20 mg/kg), midazolam (150
mg/kg), and vecuronium bromide. All of the fentanyl was
administered before sternotomy. Regarding midazolam, approx-
imately 70% of the calculated dose was administered before
sternotomy, and the balance was administered during rewarm-
ing. If required, inhaled isoflurane, intravenous nitroglycerin, or
both were used for blood pressure control before initiation of
CPB. Hypothermic CPB (to a lowest temperature of 26°C) with
a membrane oxygenator and crystalloid prime (2.0 L of lactat-
ed Ringer’s solution and 50 mEq sodium bicarbonate) was used
in all patients. Nonpulsatile flows were maintained between 2.4
and 2.8 L · min–1 · m–2, and if needed, isoflurane was used by
the perfusionist to maintain perfusion pressure in the range of 50
to 70 mm Hg. Intermittent antegrade hypothermic crystalloid
cardioplegia was used in all patients. Alpha-stat blood gas man-
agement was used in all patients. The lungs were allowed to
deflate during CPB. Separation from CPB was facilitated with
intravenous dobutamine, norepinephrine, nitroglycerin, or some
combination thereof at the discretion of the anesthesiologist
managing the case.
Hemodynamic and pulmonary measurements were obtained
at 4 times: 10 minutes after intubation (time A), 10 minutes after
sternotomy (time B), 10 minutes after sternal closure (time C),
and 60 minutes after intensive care unit (ICU) arrival (time D).
A pulmonary artery catheter (Swan-Ganz Thermodilution
Paceport Catheter; Baxter Healthcare Corporation, Irvine, Calif)
was used in all patients to facilitate data collection.
Hemodynamic measurements included heart rate, mean arterial
pressure, central venous pressure, mean pulmonary artery pres-
sure, and pulmonary artery occlusive pressure. Cardiac outputs
were obtained at end-expiration in triplicate and averaged.
Cardiac index (CI), systemic vascular resistance (SVR), pul-
monary vascular resistance (PVR), and shunt flow were calcu-
lated by using standard equations (Appendix I). Pulmonary
measurements included A-a oxygen gradient, arterial carbon
dioxide tension, dynamic lung compliance, and static lung com-
pliance computed by standard equations (Appendix II).
Mechanical ventilation parameters were standardized (respira-
tory rate, 8 breaths/min; tidal volume, 10 mL/kg; fraction of
inspired oxygen [FIO2], 1.0; positive end-expiratory pressure, +5
cm H2O; and inspiratory/expiratory ratio, 1:3) for at least 10
minutes before each measurement. In each patient the inspirato-
ry flow was adjusted so that the calculated tidal volume was
delivered during the entire inspiratory cycle (creating the lowest
peak airway pressure).
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Perioperative fluid balance and weights were recorded in all
patients. Total operating room intravenous input (eg, crystalloid
and blood products) and total operating room urine output, as
well as total intravenous input (eg, crystalloid and blood prod-
ucts) and total output (urine and chest tube) during the initial 24
postoperative hours, were recorded. All patients were weighed
3 times: immediately before transfer to the operating room
(baseline) and at 2 and 24 hours after ICU arrival. The same
sling scale (Scale-Tronix 2001 Sling Scale; Scale-Tronix, Inc,
Wheaton, Ill) was used for every weight measurement.
After completion of CABG, patients were transferred to the
ICU, where postoperative care was standardized and tracheal
extubation was accomplished at the earliest clinically appro-
priate time. Criteria for extubation in our ICU include an
appropriate sensorium, normothermia, hemodynamic stabili-
ty, adequate pulmonary function (arterial partial pressure of
oxygen, >60 mm Hg with an FIO2 of 0.4), adequate urine out-
put, and minimal chest tube output. If a patient had hyperten-
sion, tachycardia, and/or excessive movement at a time when
tracheal extubation was not yet appropriate (for any reason),
the ICU nurse was free to administer small amounts of intra-
venous midazolam. In patients who were not extubated with-
in 24 hours of ICU arrival, the reason for prolonged intuba-
tion (eg, hemodynamic instability and oxygenation
difficulties) was ascertained.
Postoperative complications and treatments were recorded
daily until hospital discharge. All patients had a creatine kinase
(CK) level assayed (by means of coupled enzymatic reactions
on the basis of Rosalki’s modification of the Oliver procedure)
and an electrocardiogram recorded at 4 AM on the first postop-
erative day. If the total CK level was greater than 200 IU/L,
CK-MB levels were assayed (by using the monoclonal anti-
body technique), and the CK-MB index was calculated (CK-
MB/total CK × 100). If the initial total CK was greater than
200 IU/L, 2 additional total CK and CK-MB levels were mea-
sured 6 and 12 hours later. Sensitivity of the CK-MB assay in
our laboratory is 0.4 ng/mL. Perioperative myocardial infarc-
tion was defined as a postoperative CK-MB index of greater
than 3.0, postoperative electrocardiographic evidence (new Q
waves or ST segment elevation) of infarction, or both.
The Pearson χ2 or Fisher exact tests were applied to cate-
goric data. One-way analysis of variance (ANOVA) was used
to test the difference between means in the 3 groups regard-
ing demographic and clinical characteristics of patients and
appropriate perioperative data. To account for repeated mea-
surements of perioperative hemodynamic and pulmonary
data, repeated-measures ANOVA was used, along with statis-
tical construct, to compare mean measurements 10 minutes
after intubation and 60 minutes after ICU arrival (with and
without the Bonferroni correction). Results are expressed as
the mean ± 1 SD or, when indicated in the appropriate table,
the number of patients, unless otherwise indicated.
Results
Thirty patients were randomized to each group. One
patient in group NS and 1 patient in group 15MP were
omitted from statistical analysis because of deviation
from the study protocol. Demographic and clinical
characteristics of patients and intraoperative data are
presented in Tables I and II, respectively. Statistical
analysis with the Pearson χ2 and Fisher exact test and
1-way ANOVA revealed no differences between groups
regarding demographic and clinical characteristics and
intraoperative data.
Perioperative hemodynamic data are presented in
Tables III and IV. Regarding Table III, repeated-mea-
sures ANOVA revealed that differences over time
(times A, B, C, and D) within groups in heart rate 
(P < .0001), mean arterial pressure (P < .0001), central
venous pressure (P < .0001), mean pulmonary artery
pressure (P < .0001), and pulmonary artery occlusive
pressure (P < .0001) were statistically significant, yet
there were no differences between groups. Regarding
Table IV, repeated-measures ANOVA revealed that dif-
ferences over time (times A, B, C, and D) within
groups in CI (P = .0001), SVR (P = .0098), PVR 
(P = .0049), and shunt flow (P < .0001) were statisti-
cally significant. When mean measurements at time A
and time D were compared by statistically constructed
repeated-measures ANOVA, differences in CI 
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(n = 29) (n = 29) (n = 30)
Preoperative history
Age, y (range) 67 ± 10 62 ± 12 67 ± 9 
(43-85) (37-81) (54-81)
Male 22 24 22
Female 7 5 8
Height (cm) 172 ± 8 173 ± 9 169 ± 11
Weight (kg) 85 ± 20 84 ± 15 79 ± 16
Smoking history (packs/y)
10-20 9 5 7
21-40 3 6 5
41-60 3 5 7
>60 5 3 5
Actively smoking 5 3 5
Never smoked 9 10 6
Preoperative medications
β-Blocker 14 18 18
Calcium channel blocker 5 3 7
Nitrate 12 16 15
ACE inhibitor 5 12 12
Digitalis preparation 4 2 7
Diuretic 7 4 7
Oral hypoglycemic 8 6 5
Insulin 3 3 5
Inhaled bronchodilators 1 2 1
None 2 1 0
ACE, Angiotensin-converting enzyme.
(P = .0006), SVR (P = .0005), and shunt flow 
(P = .0020) were statistically significant. Further statis-
tical analysis of data at time A and time D by using the
Bonferroni correction revealed significant differences
between group NS and group 30MP regarding CI 
(P < .0001), SVR (P < .0001), and shunt flow 
(P = .0030) and between group 15MP and group 30MP
regarding shunt flow (P = .0260). There were no dif-
ferences among group NS, group 15MP, and group
30MP in the number of patients requiring dobutamine
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Table II. Intraoperative data
Group NS (n = 29) Group 15MP (n = 29) Group 30MP (n = 30)
Anesthetic drugs
Fentanyl (µg/kg) 20 ± 0.3 20 ± 0.3 20 ± 0.4
Midazolam (µg/kg) 150 ± 39 150 ± 21 139 ± 23
Vecuronium (µg/kg) 431 ± 186 468 ± 167 436 ± 182
Before CPB
Isoflurane use 29 26 29
Nitroglycerin use 6 8 9
During CPB
Lowest temperature (°C) 28.8 ± 1.8 27.9 ± 1.6 27.9 ± 1.8
Highest ACT (s) 608 ± 141 653 ± 181 633 ± 129
Total heparin (mg) 295 ± 93 379 ± 99 311 ± 120
Total cardioplegia (mL) 3176 ± 1086 3034 ± 932 3309 ± 991
Countershocks required 14 16 12
Crossclamp time (min) 84 ± 18 82 ± 29 83 ± 17
CPB time (min) 108 ± 25 107 ± 30 102 ± 22
After CPB
Dobutamine use 20 23 20
Norepinephrine use 3 4 6
Nitroglycerin use 1 2 2
Isoflurane use 6 6 5
Total protamine (mg) 310 ± 84 348 ± 88 315 ± 87
Surgical data
Saphenous vein grafts (range) 1-4 0-5 1-4
LITA 26 26 24
ACT, Activated clotting time; LITA, left internal thoracic artery.
Table III. Perioperative hemodynamic data
Time A Time B Time C Time D
Heart rate (beats/min)
Group NS 58.9 ± 10.7 62.6 ± 12.6 91.9 ± 16.5 89.2 ± 12.5
Group 15MP 58.4 ± 10.2 61.0 ± 13.8 90.5 ± 15.3 86.0 ± 16.0
Group 30MP 59.9 ± 13.1 68.0 ± 13.4 90.0 ± 15.0 87.0 ± 15.7
Mean arterial pressure (mm Hg)
Group NS 68.4 ± 11.6 79.6 ± 10.9 81.0 ± 10.1 80.9 ± 13.8
Group 15MP 71.9 ± 9.7 82.1 ± 12.6 77.4 ± 8.9 78.3 ± 14.4
Group 30MP 73.3 ± 7.1 79.3 ± 10.8 76.3 ± 12.2 73.2 ± 12.2
Central venous pressure (mm Hg)
Group NS 13.2 ± 3.3 12.8 ± 4.8 13.5 ± 4.3 8.9 ± 3.7
Group 15MP 13.5 ± 3.4 14.0 ± 3.4 14.4 ± 3.7 8.4 ± 2.6
Group 30MP 12.2 ± 2.8 13.1 ± 3.6 14.3 ± 3.9 8.2 ± 4.1
Mean pulmonary artery pressure (mm Hg)
Group NS 22.5 ± 4.8 22.6 ± 5.3 22.2 ± 5.0 18.7 ± 4.2
Group 15MP 22.8 ± 7.6 23.4 ± 6.0 24.1 ± 4.4 18.8 ± 5.3
Group 30MP 21.0 ± 4.9 24.1 ± 7.5 24.3 ± 6.0 18.6 ± 4.4
Pulmonary artery occlusive pressure (mm Hg)
Group NS 15.7 ± 4.1 15.5 ± 5.4 8.1 ± 5.7 11.3 ± 3.9
Group 15MP 14.8 ± 3.4 15.6 ± 3.3 7.8 ± 4.2 10.4 ± 3.0
Group 30MP 14.5 ± 3.6 15.0 ± 4.4 9.5 ± 5.3 11.1 ± 3.8
Time A, 10 minutes after intubation; Time B, 10 minutes after sternotomy; Time C, 10 minutes after sternal closure; Time D, 60 minutes after ICU arrival.
(10, 12, and 15, respectively), norepinephrine (8, 9, and
9, respectively), or nitroglycerin (8, 3, and 7, respec-
tively) during the initial 24 hours of ICU stay.
Perioperative pulmonary data are presented in Table
V. Repeated-measures ANOVA revealed that differ-
ences over time (times A, B, C, and D) within groups
in A-a oxygen gradient (P < .0001), arterial carbon
dioxide tension (P < .0001), dynamic lung compliance
(P < .0001), and static lung compliance (P < .0001)
were statistically significant, yet there were no differ-
ences between groups.
Perioperative fluid balance and weights are presented
in Table VI. One-way ANOVA revealed no differences
between groups regarding perioperative fluid balance.
All 3 groups experienced equivalent significant (P <
.0001) postoperative increases in weight.
Extubation times are presented in Table VII. When
all extubated patients and patients extubated within 24
hours of ICU arrival were analyzed, there was no sta-
tistically significant difference between groups despite
a trend toward prolonged extubation times in patients
receiving methylprednisolone. However, when patients
extubated within 12 hours of ICU arrival were ana-
lyzed, 1-way ANOVA revealed a statistically signifi-
cant difference in extubation times (P = .025) between
groups, and Bonferroni correction comparing group
NS with group 30MP yielded a P value of .038.
Midazolam administration from arrival in the ICU to
extubation was similar among group NS (5.4 ± 7.2
mg), group 15MP (3.9 ± 4.7 mg), and group 30MP (2.9
± 5.6 mg). More patients in group 30MP (14) required
no midazolam before extubation than in group 15MP
(11) and group NS (7).
During the initial 24 ICU hours, 1-way ANOVA
revealed a statistically significant difference in peak
postoperative blood glucose level (P = .016) among
patients in group NS (234 ± 96 mg/dL), group 15MP
(292 ± 93 mg/dL), and group 30MP (311 ± 90 mg/dL).
Postoperative atrial fibrillation occurred in 9 group NS
patients, 8 group 15MP patients, and 9 group 30MP
patients. One patient in group NS had a perioperative
myocardial infarction (electrocardiographic changes) yet
otherwise had an uneventful postoperative course. One
patient in group NS and 1 patient in group 30MP had a
postoperative cerebral infarction. Both patients were
eventually discharged to a chronic care facility. One
patient in group NS died. This patient was initially extu-
bated uneventfully yet became asystolic late on the first
postoperative day. Re-exploration revealed dysfunction-
al saphenous vein grafts, and the patient died on the fifth
postoperative day. Of the 88 patients, 87 were eventual-
ly discharged from the hospital. The mean duration of
postoperative hospital stay among patients in group NS
(6.5 ± 4.6 days), group 15MP (6.0 ± 4.8 days), and group
30MP (6.7 ± 3.4 days) was similar.
Discussion
This prospective randomized double-blind placebo-
controlled clinical study reveals that administration of
methylprednisolone to patients undergoing elective
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Table IV.  Perioperative hemodynamic data 
Time A Time B Time C Time D
CI (L · min–1 · m–2)
Group NS 2.4 ± 0.7 2.5 ± 0.7 2.7 ± 1.0 2.6 ± 0.7
Group 15MP 2.4 ± 0.6 2.6 ± 0.7 3.2 ± 0.9 3.1 ± 0.8
Group 30MP 2.3 ± 0.4 2.5 ± 0.7 3.4 ± 1.2 3.4 ± 1.0*
SVR (dynes · s–1 · cm–5)
Group NS 1027 ± 396 1225 ± 452 1181 ± 564 1260 ± 550
Group 15MP 1027 ± 283 1171 ± 382 875 ± 316 968 ± 324
Group 30MP 1181 ± 345 1201 ± 388 883 ± 406 913 ± 470*
PVR (dynes · s–1 · cm–5)
Group NS 125 ± 47 133 ± 56 252 ± 147 124 ± 67
Group 15MP 139 ± 101 141 ± 111 232 ± 102 118 ± 67
Group 30MP 123 ± 61 168 ± 121 213 ± 129 96 ± 46
Shunt flow (%)
Group NS 15.9 ± 6.1 16.0 ± 6.0 21.6 ± 9.1 23.1 ± 7.7
Group 15MP 15.3 ± 7.6 14.1 ± 5.4 21.4 ± 9.7 24.1 ± 8.5
Group 30MP 14.9 ± 6.9 16.8 ± 6.6 27.3 ± 9.6 30.1 ± 8.8†‡
Time A, 10 minutes after intubation; Time B, 10 minutes after sternotomy; Time C, 10 minutes after sternal closure; Time D, 60 minutes after ICU arrival.
*P < .0001, group 30MP versus group NS.
†P = .0030, group 30MP versus group NS.
‡P = .0260, group 30MP versus group 15MP.
CABG with CPB increases postoperative CI, decreases
postoperative SVR, increases postoperative shunt flow,
is unable to prevent postoperative pulmonary dysfunc-
tion (increased A-a oxygen gradient and decreased
dynamic and static lung compliance) or prevent post-
operative weight gain, initiates postoperative hyper-
glycemia, and prolongs tracheal extubation time. Thus,
methylprednisolone, as used in this investigation, offers
no clinical benefits to patients undergoing elective
CABG with CPB and may in fact be detrimental by ini-
tiating postoperative hyperglycemia and possibly hin-
dering early postoperative tracheal extubation.
Patients undergoing cardiac surgery experience an
abnormal whole-body inflammatory response after ini-
tiation of CPB, which causes detrimental postoperative
changes in pulmonary function and hemodynamics.1
Inhibition of detrimental CPB-induced physiologic
effects may be possible with corticosteroids. In the
1960s, methylprednisolone became the drug of choice
because of its clinical efficacy in shock and sepsis and
its advantageous side effect profile.5 The dose used, 30
mg/kg, was empirically chosen and remains the stan-
dard. However, a supplemental dose must be adminis-
tered at initiation of CPB to maintain adequate plasma
levels of drug into the postoperative period.6 Although
many studies have investigated use of methylpred-
nisolone in preventing detrimental CPB-induced phys-
iologic effects, it is still unclear whether the drug truly
is beneficial in this setting.7-32
Whether administration of methylprednisolone
before CPB enhances postoperative hemodynamic sta-
bility remains controversial.* The observed hemody-
namic changes in this investigation regarding CI, SVR,
and shunt flow were similar to those in our previous
investigation.3 Other investigators have documented
increases in CI,24,32 decreases in SVR,24,29,32 increases
in shunt flow,25,33,34 and decreased incidence of
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Table V.  Perioperative pulmonary data
Time A Time B Time C Time D
A-a oxygen gradient (mm Hg)
Group NS 254.2 ± 95.1 246.7 ± 91.4 352.3 ± 123.0 393.3 ± 83.7
Group 15MP 219.3 ± 111.9 219.4 ± 96.1 318.8 ± 127.4 364.1 ± 106.0
Group 30MP 233.7 ± 119.6 243.7 ± 128.9 373.6 ± 145.5 413.7 ± 126.5
Arterial carbon dioxide tension (mm Hg)
Group NS 35.9 ± 4.4 34.2 ± 5.9 38.0 ± 4.9 45.2 ± 7.7
Group 15MP 37.5 ± 4.2 35.1 ± 4.3 39.8 ± 4.9 46.2 ± 6.7
Group 30MP 36.8 ± 3.6 35.4 ± 4.1 40.4 ± 4.5 45.5 ± 6.4
Dynamic lung compliance (mL/cm H2O)
Group NS 49.4 ± 14.3 47.7 ± 12.8 43.2 ± 12.2 33.1 ± 8.5
Group 15MP 48.3 ± 10.5 47.0 ± 9.2 41.4 ± 8.3 36.5 ± 6.1
Group 30MP 48.1 ± 12.6 47.7 ± 12.9 41.7 ± 10.1 35.7 ± 6.4
Static lung compliance (mL/cm H2O)
Group NS 71.4 ± 27.7 68.2 ± 28.7 61.5 ± 26.0 49.3 ± 13.1
Group 15MP 69.4 ± 41.0 61.6 ± 17.3 55.5 ± 24.1 57.0 ± 13.9
Group 30MP 73.6 ± 44.6 75.4 ± 59.4 63.2 ± 38.3 54.8 ± 13.3
Time A, 10 minutes after intubation; Time B, 10 minutes after sternotomy; Time C, 10 minutes after sternal closure; Time D, 60 minutes after ICU arrival.
Table VI. Perioperative fluid balance and weights
Group NS (n = 29) Group 15MP (n = 29) Group 30MP (n = 30)
Total OR IV input (mL) 2660 ± 505 3096 ± 1739 3097 ± 964
Total OR urine output (mL) 844 ± 564 976 ± 770 819 ± 583
Initial 24-h ICU total IV input (mL) 3714 ± 1450 3671 ± 1677 3491 ± 1432
Initial 24-h ICU total output (mL) 3281 ± 1004 3668 ± 1301 3491 ± 1193
Baseline weight (kg) 85.5 ± 20.3 84.0 ± 14.9 78.9 ± 16.4
Weight 2 h after ICU arrival (kg) 90.7 ± 18.4* 90.9 ± 15.3* 85.6 ± 16.8*
Weight 24 h after ICU arrival (kg) 91.3 ± 20.3* 88.7 ± 15.7* 84.6 ± 17.1*
OR, Operating room; IV, intravenous.
*P < .0001 when compared with baseline weight.
*References 3,5,6,12,19,22,24,28-30,32
arrhythmias28 when methylprednisolone is used in this
setting. Postoperative vasodilation, although having
certain beneficial physiologic effects (decreased after-
load and decreased left ventricular end-diastolic vol-
ume and pressure), may increase postoperative use of
pharmacologic agents to support mean arterial pres-
sure,3 increase postoperative A-a oxygen gradient
because of increased shunt fraction,2,3 or both. Indeed,
after cardiac surgery, there is a significant correlation 
(r = 0.82) between shunt flow and A-a oxygen gradient.33
Whether administration of methylprednisolone
before CPB attenuates pulmonary damage is also con-
troversial.2,15,16,25,26 Some investigators document
decreased neutrophil activation,16 decreased postopera-
tive radiographic abnormalities,26 and improvement in
postoperative oxygenation2 in patients who received
methylprednisolone, whereas others reveal the drug
does not prevent interleukin 8–mediated pulmonary
neutrophil infiltration15 or postoperative oxygenation
abnormalities.25 As in our previous investgation,2 we
again found that methylprednisolone was unable to
prevent postoperative increases in A-a oxygen gradient
and postoperative decreases in dynamic and static lung
compliance.
The stimulus for this investigation was the unexpect-
ed findings of our previous investigation.2,3 Our group
was the first to rigorously examine use of methylpred-
nisolone in patients undergoing cardiac surgery and
early extubation, and we found that the drug signifi-
cantly prolonged extubation time when compared with
placebo controls (12.8 ± 4.9 hours vs 10.1 ± 5.2 hours,
respectively; P = .05).2,3 Using the same perioperative
study protocol (with an additional group receiving the
drug at half the original dose), we again found that
methylprednisolone significantly prolonged extubation
time. Because large doses of methylprednisolone may
induce sodium and water retention, which may initiate
pulmonary edema in susceptible patients,4 we also
assessed perioperative fluid balance and weights.
However, there was no difference between groups
regarding these perioperative variables. Two previous
observational studies further suggest that methylpred-
nisolone prolongs extubation time in this setting.10,30
One found that patients who received 1.0 g of methyl-
prednisolone immediately before CPB followed by 4
doses of dexamethasone (4.0 mg each) every 6 hours
after CPB had prolonged extubation times compared
with control patients who did not receive steroids (13.1
± 2.3 hours vs 10.5 ± 1.0 hours, respectively), although
the difference was not statistically significant.10 The
other found that patients who received 30 mg/kg
methylprednisolone after the induction of anesthesia
required significantly prolonged respiratory support in
the immediate postoperative period compared with his-
torical controls (85 ± 181 hours vs 27 ± 16 hours,
respectively; P = .05).30
Methylprednisolone is an attractive agent for poten-
tial suppression of the systemic inflammatory response
associated with CPB because of its beneficial effects on
neutrophil kinetics and function and because it repre-
sents one of the few therapeutic drugs that possess
multi-inhibitory effects on numerous components of
the inflammatory response.35 Potential anti-inflam-
matory effects of methylprednisolone, when used in
this manner, include decreased complement activa-
tion,10,19,21 decreased interleukin 6 release,7,11,12
decreased interleukin 8 release,8-10,12 increased inter-
leukin 10 release,8,9 decreased tumor necrosis factor
release,9,11-13 and decreased neutrophil integrin
CD11b up-regulation,13,14 among others. However,
although results from animal models appear promis-
ing, definitive clinical benefits in human subjects have
yet to be demonstrated. Our investigation shows that
the drug confers no clinical benefit and may in fact be
detrimental by delaying postoperative extubation (for
undetermined reasons) and initiating postoperative
hyperglycemia. Furthermore, methylprednisolone ad-
ministration is not without other potential risks, which
include gastritis, gastrointestinal bleeding, impaired
wound healing, increased risk of infection, adverse
psychiatric effects, avascular bone necrosis, and aggra-
vation of ischemic brain injury (irrespective of hyper-
glycemia).36
In conclusion, this prospective randomized double-
blind placebo-controlled clinical study reveals that
administration of methylprednisolone to patients
undergoing elective CABG with CPB increases post-
operative CI, decreases postoperative SVR, increases
postoperative shunt flow, is unable to prevent postoper-
ative pulmonary dysfunction (increased A-a oxygen
gradient and decreased dynamic and static lung com-
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Table VII.  Extubation times
All extubated patients
Group NS, h (n = 27) 7.0 ± 5.1
Group 15MP, h (n = 28) 14.9 ± 34.7
Group 30MP, h (n = 30) 16.3 ± 38.7
Patients extubated within 24 h of ICU arrival
Group NS, h (n = 27) 7.0 ± 5.0
Group 15MP, h (n = 27) 8.4 ± 5.4
Group 30MP, h (n = 29) 9.3 ± 5.0
Patients extubated within 12 h of ICU arrival
Group NS, h (n = 25) 5.7 ± 2.3
Group 15MP, h (n = 21) 5.9 ± 2.2
Group 30MP, h (n = 24) 7.5 ± 2.7*
*P = .038, group 30MP versus group NS.
pliance) or postoperative weight gain, initiates postop-
erative hyperglycemia, and prolongs tracheal extuba-
tion time (for undetermined reasons). Thus, methyl-
prednisolone, as used in this investigation, offers no
clinical benefits to patients undergoing elective CABG
with CPB and may in fact be detrimental by initiating
postoperative hyperglycemia and possibly hindering
early postoperative tracheal extubation.
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Appendix I. Hemodynamic standard equations
Cardiac index: CI = 
Systemic vascular resistance: SVR = × 80
Pulmonary vascular resistance: PVR = × 80
Shunt flow (%): = 
CO, Cardiac output; BSA, body surface area; MAP, mean arterial pressure;
CVP, central venous pressure; PAP, pulmonary artery pressure; PCWP, pul-
monary capillary wedge pressure; CcO2, end-capillary oxygen content; CaO2,














Appendix II.  Pulmonary standard equations
Alveolar–arterial O2 gradient (mm Hg): P(A-a)O2 = PAO2 – PaO2
PAO2 = PIO2 – 
PIO2 = FIO2 × (PB – 47)
Dynamic lung compliance (mL/cm H2O): Cd = 
Static lung compliance (mL/cm H2O): Cs = 
PAO2, Alveolar PO2, PaO2, arterial PO2; PaCO2, arterial PCO2; 0.8, assumed res-
piratory quotient; PEEP, positive end-expiratory pressure.
Tidal volume

P plateau – PEEP
Tidal volume

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